Oculis Holding AG announced that the final patient visit in its Phase 3 DIAMOND program for the OCS‑01 eye drops has been completed. The 52‑week, double‑masked, randomized, multi‑center trials are now fully enrolled, positioning the company to report topline results in June 2026 and to potentially file a U.S. NDA in the fourth quarter.
The milestone de‑risks the OCS‑01 development pathway and moves the company closer to a first‑in‑class, non‑invasive topical therapy for diabetic macular edema (DME). With an estimated U.S. patient population of more than 1.8 million and a market opportunity of roughly $3 billion, a successful outcome could reshape DME management and provide a substantial new revenue stream for Oculis.
CEO Riad Sherif said, "The completion of the last patient visit in both DIAMOND Phase 3 trials represents a pivotal milestone as we advance towards anticipated topline results in June. This achievement reflects our commitment to advancing OCS‑01 as a potential first‑in‑class eye drop therapy for DME, a leading cause of blindness in working‑age adults." Chairperson Arshad M. Khanani added, "DME continues to pose a major challenge in clinical practice, with many patients inadequately served by current therapies due to high treatment burden and sub‑optimal response. A non‑invasive topical option like OCS‑01 could significantly reshape how DME is managed."
The announcement did not trigger a significant market reaction, reflecting the routine nature of a clinical milestone announcement. However, the event is a key de‑risking step that could influence future valuation and investor expectations as the company moves toward regulatory filing.
Oculis also continues to develop other late‑stage assets, including Privosegtor for optic neuropathies and Licaminlimab for dry eye disease, underscoring a diversified pipeline. The company reported a net loss of CHF 98.96 million ($119.1 million) for the full year 2025 and held CHF 213.0 million ($268.7 million) in cash and investments as of December 31 2025, providing a runway into 2029.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.